Is APUS or BCRX more undervalued in 2026?

CirclFi compares Apimeds Pharmaceuticals US, Inc (APUS) and BioCryst Pharmaceuticals, Inc. (BCRX) using 13 institutional-grade valuation models. APUS has a Quality of Company score of 4.8/10 while BCRX scores 6.9/10.

Which is a better buy — APUS or BCRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do APUS and BCRX valuations compare?

APUS at $1.36 and BCRX at $9.10 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

APUS vs BCRX Valuation Comparison 2026 — Intrinsic Value Analysis

APUS

Drug Manufacturers - Specialty & Generic

Apimeds Pharmaceuticals US, Inc

Quality

4.8

out of 10

Value Trap

SAFE

Price

$1.36

Last close

Models

7/13

Active

BCRX

Drug Manufacturers - Specialty & Generic

BioCryst Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$9.10

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	APUS Fair Value	APUS Upside	BCRX Fair Value	BCRX Upside
Bayesian DCF	Intrinsic	$0.39	-71.3%	$14.22	+66.7%
Earnings Power Value	Intrinsic	—	—	$2.33	-74.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.88	+185.2%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for APUS vs BCRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APUS vs BCRX — Which Stock Is More Undervalued?

BCRX scores higher with a 6.9/10 quality rating vs APUS's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Apimeds Pharmaceuticals US, Inc (APUS) and BioCryst Pharmaceuticals, Inc. (BCRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APUS currently trades at $1.36 with a QOC of 4.8/10, while BCRX trades at $9.10 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).